David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the lifespan of millions with COPD. If you or someone close to you suffers from ...

New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy. At the ERS 2025 ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

The chronic obstructive pulmonary disease (COPD) guidelines recommend selecting initial treatment based on the severity of respiratory symptoms or exacerbation history. However, some patients still ...

If you or someone close to you suffers from chronic shortness of breath, persistent cough, and reduced physical fitness, there is a chance it may be COPD. This is a serious lung disease affecting ...

—Early evidence suggests promise for a novel COPD treatment using autologous P63+ lung progenitor cell. This small study found the bronchoscopic transplantation of cultured P63+ cells to be safe and ...

At the ERS 2025 Congress, the world’s largest annual meeting on respiratory diseases, attended by international experts, one of the hot topics in pulmonary medicine was discussed this year—the ...